Aytu BioPharma, Inc. (AYTU)

Aytu BioPharma Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cash & Equivalents	20.11	20.01	22.99	19.36	49.65	48.08
Cash & Short-Term Investments	20.11	20.01	22.99	19.36	49.65	48.08
Cash Growth	0.72%	-12.96%	18.72%	-61.01%	3.26%	335.36%
Receivables	23.16	23.62	28.94	21.71	28.18	5.63
Inventory	11.74	12.63	12	10.85	16.34	10
Prepaid Expenses	5.73	5.64	7.16	7.38	9.78	5.72
Restricted Cash	-	-	-	-	0.25	0.25
Other Current Assets	-	-	-	0.63	1.04	5.74
Total Current Assets	60.74	61.89	71.08	59.93	105.23	75.42
Property, Plant & Equipment	1.92	1.52	3.87	6.3	8.7	0.89
Goodwill	-	-	-	-	65.8	28.09
Other Intangible Assets	51.21	52.45	58.97	70.63	85.46	48.86
Long-Term Deferred Tax Assets	-	0.76	1.38	-	-	-
Other Long-Term Assets	1.97	1.47	1.17	0.77	0.47	0.03
Total Assets	115.83	118.1	136.46	137.62	265.67	153.29
Accounts Payable	13.51	10.44	13.48	10.99	19.26	11.64
Accrued Expenses	33.72	22.69	25.28	25.71	30.72	10.3
Short-Term Debt	4.27	2.4	1.56	3.81	7.93	-
Current Portion of Long-Term Debt	1.86	1.86	-	-	16.57	0.98
Current Portion of Leases	-	0.71	1.34	0.1	0.1	0.3
Other Current Liabilities	7.89	24.14	27.35	23.84	34.86	5.54
Total Current Liabilities	61.25	62.23	69.02	64.44	109.44	28.76
Long-Term Debt	10.43	10.88	14.71	14.2	-	-
Long-Term Leases	-	0.58	0.83	0.08	0.18	0.73
Long-Term Deferred Tax Liabilities	-	0.76	1.38	-	-	-
Other Long-Term Liabilities	14.32	15.94	11.17	14.59	18.48	28.79
Total Liabilities	86.01	90.38	97.11	93.32	128.1	58.28
Common Stock	0	0	0	-	0	0
Additional Paid-In Capital	348.32	347.69	343.49	331.39	315.86	215.02
Retained Earnings	-318.5	-319.97	-304.13	-287.08	-178.3	-120.01
Total Common Equity	29.83	27.72	39.36	44.31	137.57	95.02
Shareholders' Equity	29.83	27.72	39.36	44.31	137.57	95.02
Total Liabilities & Equity	115.83	118.1	136.46	137.62	265.67	153.29
Total Debt	16.56	16.42	18.45	18.19	24.78	2.01
Net Cash (Debt)	3.55	3.59	4.53	1.17	24.87	46.08
Net Cash Growth	-7.65%	-20.86%	286.86%	-95.29%	-46.03%	317.19%
Net Cash Per Share	0.62	0.65	1.36	0.80	29.70	203.91
Filing Date Shares Outstanding	6.15	6.15	5.53	3.12	1.38	0.63
Total Common Shares Outstanding	5.97	5.97	5.52	1.93	1.37	0.63
Working Capital	-0.51	-0.34	2.06	-4.51	-4.2	46.66
Book Value Per Share	4.99	4.64	7.13	22.97	100.08	151.01
Tangible Book Value	-21.38	-24.74	-19.61	-26.32	-13.7	18.07
Tangible Book Value Per Share	-3.58	-4.14	-3.55	-13.65	-9.97	28.72
Machinery	-	2.78	4.39	4.45	5	0.51
Construction In Progress	-	-	0.11	-	0.2	-
Leasehold Improvements	-	0.04	1	1	0.96	0.23

Source: S&P Capital IQ. Standard template. Financial Sources.